• 1海南省文昌市人民醫(yī)院急診科,海南文昌 571300;2海南省人民醫(yī)院心內(nèi)科, 海南?？?570311;

目的:探討并研究纖溶系統(tǒng)與纖維蛋白原在不穩(wěn)定型心絞痛(UA)患者發(fā)病中的臨床價值。方法:對108例不穩(wěn)定型心絞痛患者和42穩(wěn)定型心絞痛(SA)患者體內(nèi)纖溶酶原激活物抑制劑-1(PAI-1)、組織型纖溶酶原激活劑(t-PA)、纖維蛋白原(FIB)水平進行檢測,并與20例正常對照者進行對照,探討其臨床意義。結(jié)果:UA患者體內(nèi)PAI-1、FIB水平明顯高于SA患者和正常對照者,UA患者中有心血管事件發(fā)生者也明顯高于無心血管事件發(fā)生者;UA患者體內(nèi)t-PA水平明顯低于SA患者和正常對照者,UA患者中有心血管事件發(fā)生者也明顯低于無心血管事件發(fā)生者。結(jié)論:UA 患者纖溶系統(tǒng)功能異常和FIB水平升高程度較SA患者更加明顯,并且UA患者的心血管事件發(fā)生可能與溶系統(tǒng)功能異常和FIB水平升高相關(guān)。

引用本文： 梁振煉,馬建林. 纖溶系統(tǒng)與纖維蛋白原在不穩(wěn)定型心絞痛患者發(fā)病中的臨床意義. 華西醫(yī)學, 2009, 24(7): 1719-1721. doi: 復制

版權(quán)信息： ?四川大學華西醫(yī)院華西期刊社《華西醫(yī)學》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. LIBBY P. Current concepts of the pathogenesis of the acute coronary syndrome[J]. Circulation, 2001,104(3):365-372.
2. YAZICI M, DEMIRCAN S, DURNA K,et al. Relationship Between Myocardial Injury and Soluble PSelectin in NonST Elevation Acute Coronary Syndromes[J].Circulation Journal, 2005,69(5):1346-1350.
3. TARNOK A. Diurnal Variation of Soluble E-and P-Selectin, and Intercellular Adhesion Molecule-1 in Patients with and without Coronary Artery Disease[J]. Cardiology,2004,102(4):6308-6312.
4. TUSS H, LINDAHL B, SIEGBAHN A, et al.Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease[J].Eur Heart J, 1998,19(Suppl H):H11-17.
5. GRUNDT H, NILSEN DW, HETLAND O, et al. Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction[J]. Am Heart J, 2004,147 (2):8702-8708.
6. DECALF V, SABBAH L, LAFONT A, et al. GpⅡb/Ⅲa receptor antagonists in acute coronary syndromes with no ST elevention[J]. Arch Mal Coeur Vaiss, 2007,100(12):1006-1012.
7. 馬建林,王圣,李新明,等.冠心病患者D二聚體、血小板膜糖蛋白測定及意義.中華心血管并雜志,2005,33(8):724-726.
8. KEATING F K, WHITAKER D A, SOBEL B E,et al. Augmentation of inhibitory effects of glycoprotein IIbIIIa antagonists in patients with diabetes[J]. Thrombosis Research, 2004,113 (1):3848-3853.
9. ORGAZ S, CARRASCO C, BURGOS M E, et al. Proteomic analysis of plasma from patients during an acute coronary syndrome[J]. J Am Coll Cardio, 2004,44(8) 1091-1097.
10. DEVARAJ S, XU D Y, JIALAL I. Creactive protein increase plasminogen activator inhibitor 1 expression and activity in human aortic endothelial cell:implication for the metabolic syndrome and atherothrombosis[J]. Circulation,2003,107(3):398-404.
11. CHNG T L, PUMPLIN D W, HOLLTON L H, et al. Prevention of microsurgical anastomotic thrombosis using aspirin,heparin,and the glycoprotein Ⅱb/Ⅲa inhibitor tirofiban[J]. Plast Reconstr Surg, 2007,120(5):1281-1288.
12. TOSS H, LINDAHL B, SIEGHAHN A, et al. Prognostic influence of increased fibringen and Creactive protein levels in unstable coronary artery disease[J]. Circulation,1997,96(12):4204-4210.
  1. 1. LIBBY P. Current concepts of the pathogenesis of the acute coronary syndrome[J]. Circulation, 2001,104(3):365-372.
  2. 2. YAZICI M, DEMIRCAN S, DURNA K,et al. Relationship Between Myocardial Injury and Soluble PSelectin in NonST Elevation Acute Coronary Syndromes[J].Circulation Journal, 2005,69(5):1346-1350.
  3. 3. TARNOK A. Diurnal Variation of Soluble E-and P-Selectin, and Intercellular Adhesion Molecule-1 in Patients with and without Coronary Artery Disease[J]. Cardiology,2004,102(4):6308-6312.
  4. 4. TUSS H, LINDAHL B, SIEGBAHN A, et al.Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease[J].Eur Heart J, 1998,19(Suppl H):H11-17.
  5. 5. GRUNDT H, NILSEN DW, HETLAND O, et al. Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction[J]. Am Heart J, 2004,147 (2):8702-8708.
  6. 6. DECALF V, SABBAH L, LAFONT A, et al. GpⅡb/Ⅲa receptor antagonists in acute coronary syndromes with no ST elevention[J]. Arch Mal Coeur Vaiss, 2007,100(12):1006-1012.
  7. 7. 馬建林,王圣,李新明,等.冠心病患者D二聚體、血小板膜糖蛋白測定及意義.中華心血管并雜志,2005,33(8):724-726.
  8. 8. KEATING F K, WHITAKER D A, SOBEL B E,et al. Augmentation of inhibitory effects of glycoprotein IIbIIIa antagonists in patients with diabetes[J]. Thrombosis Research, 2004,113 (1):3848-3853.
  9. 9. ORGAZ S, CARRASCO C, BURGOS M E, et al. Proteomic analysis of plasma from patients during an acute coronary syndrome[J]. J Am Coll Cardio, 2004,44(8) 1091-1097.
  10. 10. DEVARAJ S, XU D Y, JIALAL I. Creactive protein increase plasminogen activator inhibitor 1 expression and activity in human aortic endothelial cell:implication for the metabolic syndrome and atherothrombosis[J]. Circulation,2003,107(3):398-404.
  11. 11. CHNG T L, PUMPLIN D W, HOLLTON L H, et al. Prevention of microsurgical anastomotic thrombosis using aspirin,heparin,and the glycoprotein Ⅱb/Ⅲa inhibitor tirofiban[J]. Plast Reconstr Surg, 2007,120(5):1281-1288.
  12. 12. TOSS H, LINDAHL B, SIEGHAHN A, et al. Prognostic influence of increased fibringen and Creactive protein levels in unstable coronary artery disease[J]. Circulation,1997,96(12):4204-4210.